Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management.

Authors:
Fawaz A; Abdel-Rahman O.

Journal:
Cancer Manag Res

Publication Year: 2022

DOI:
10.2147/CMAR.S340719

PMCID:
PMC9805723

PMID:
36597515

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Cancer Manag Res

Abbreviation: Cancer Manag Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer.
Wu X; Li S; Yang Y and 2 more (2024) - Transparency Score: 3/6
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractor…
Bai H; Wang WH; Zhou FF and 2 more (2024) - Transparency Score: 3/6
High Expression of WT1 and Low Expression of p53 in Archived Blocks of Children with Wilms Tumor in…
Ssenkumba B; Atwiine B; Mitala Y and 5 more (2024) - Transparency Score: 3/6
Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the …
Yang F; Li C; Qiu Y and 7 more (2024) - Transparency Score: 3/6
ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cance…
Wang Y; Ma C; Yang X and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Omar Abdel-Rahman is part of the advisory board for Amgen, Eisai, Ipsen, Roche, Lilly, and Bayer, outside the submitted work. The authors report no other conflicts of interest in this work."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025